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Objective. The pathogenesis of abdominal aortic aneurysm (AAA) is complex and different factors, including calcification, are
linked to increased complications. This study was conducted in order to verify if classical risk factors for AAA and cell blood
count parameter could help in the identification of calcification progression of the aneurysm. Design. Risk factors were collected
and cell blood count was performed in patients with AAA and patients were analyzed for the presence of aorta calcification
using CT angiography. Results. We found no association of calcification grade with risk factors for AAA but we found a strong
association between MCV, MCH, and calcification grade. Instead, no association was found with the other parameter that we
analyzed. Conclusions. In this study, we demonstrate that biomarkers such as MCV and MCH could have potential important
information about AAA calcification progression and could be useful to discriminate between those patients that should undergo
a rapid imaging, thus allowing prompt initiation of treatment of suspicious patients that do not need imaging repetition.
To the memory of Professor Adolfo Turano: “Accedit quod patrem plus etiam quam non modo tu sed quam ipse scit amo” (“I
love my father more than, not only you, but even he knows”) (MT Cicerone)
1. Introduction
Abdominal aortic aneurysm (AAA) is largely an asymp-
tomatic disease, but the aneurysm may rupture with subse-
quent mortality rates of at least 80% if early detection and
elective AAA repair are not performed [1–4]. Most of the
literature is devoted to the study of the diameter of AAA since
it is known that risk of rupture increases exponentially with
maximal aortic diameter, and different authors have reported
a relationship with risk factors such as age, smoking history,
family history of cardiovascular disease, and dyslipidemia
and also with some biomarkers [5–8]. Nevertheless, since
aneurysm size does not completely represent the natural
history of AAA [5–8] other risk factors, including calcifi-
cation, have been investigated. Different degrees of mural
calcification exist and the gravity of calcification seems to
be associated with the risk of rupture [9–11]. Actually no
prognostic indices to evaluate progression of calcification
exist and repetition of imaging to monitor AAA expansion
is necessary, with some important limitations such as cost or
availability [12, 13]. Lack of biomarkers for risk stratification
of patients with AAA impedes development of novel person-
alized therapies and interventions since, in every patient with
a not-yet “surgical” AAA, there are no clear predictors of a
fast or slow progression of its own, AAA; that is, the best
interval between a radiological check and the next step is not
defined. Different authors have suggested a link between risk
factors such as smoking history, obesity, glucose tolerance,
dyslipidemia, chronic obstructive pulmonary disease, and
renal failure and cardiovascular morbidity and mortality,
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Table 1
Variables p value
Smoking history 0.1088
Obesity 1.0000
Glucose tolerance 0.9164
Dislipidemia 0.7970
Family history cardiovascular disease 0.1520
Chronic obstructive pulmonary disease 0.7771
Renal failure 0.5304
Localization 0.5078
p values were computed using Pearson’s Chi-squared test.
together with some biomarkers such as RBC indices, WBC
counts with differentials, platelet counts and neutrophil-to-
lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio
(PLR), while no evidence exists in the literature about a
possible association betweenAAAcalcification and cell blood
count (CBC) parameter even if it is a simple economic
and extensively used basic hematological test [14–18]. The
aim of our study is to evaluate if classical risk factor and
biomarkers associated with AAA [14, 15] can be associated
with AAA calcification grade since an accessible and cost-
effective measure such as a blood test predicting subsequent
AAA progression in calcification could be used to rule in
and/or rule out patients for more expensive MR and CT
angiography, with benefit for patients and caregivers andwith
important reduction of cost.
2. Methods
2.1. Patients. The study enrolled 149 Caucasian patients
admitted to the Vascular Surgery of Brescia University
“Spedali Civili” hospital in Brescia, Northern Italy, between
2014 and 2016, forAAA surgical repair. Risk factors, including
age (continuous), gender (male versus female), and smoking
(current versus never or former), were collected. If patients
had a body max index > 25 kg/m2 they were classified as
obese and affected by diabetes mellitus if they had glycated
hemoglobin > 6.5% or if they were prescribed antidiabetic
drugs.Dyslipidemiawas defined as fasting serum low-density
lipoprotein cholesterol > 140mg/dl, triglycerides > 150mg/dl,
or high-density lipoprotein cholesterol < 40mg/dl or if
patients were prescribed lipid-lowering medications. Finally,
patients were classified with renal failure when serum creati-
nine was >2mg/dl and with chronic obstructive pulmonary
disease if they had, during spirometry with a forced expira-
tory volume in one second, a vital capacity of 70% or less.
If cardiovascular disease was present within second-degree
relatives, this was recorded as family history of cardiovascular
disease. AAA aneurysms were classified on the basis of the
anatomical localization and shape. Demographic data and
medical history of each patient were collected. Institutional
ethic committees approved the study, and all patients pro-
vided a written informed consent (approval reference num-
ber 1353). Participants did not receive any form of financial
compensation.The study conformed to the ethical guidelines
of the “World Medical Association Declaration of Helsinki-
Ethical Principles for Medical Research Involving Human
Subjects” adopted by the 18th World Medical Association
General Assembly, Helsinki, Finland, June 1964, and revised
in Tokyo in 2004.
2.2. Imaging Assessment of Aneurysm Calcifications. Aneu-
rysm calcifications were qualitatively assessed by the consen-
sus of two physicians: a radiologist and a resident in vascular
surgery based on the CT angiography performed within one
month before surgery. By a single radiologist, calcifications
were evaluated on axial multiplanar reconstructions using a
10mm thickmaximum intensity projection on three different
levels: upper,middle, and lower portion of the aneurysm.Cal-
cification grade was scored as I when calcifications covered
less than one-third of aortic circumference and as II when
they covered more than one-third of aortic circumferences.
The score at the upper and lower aneurysm level was
multiplied by a factor of 0.5 in order to reflect the changes
in the aneurysm circumference due to the aneurysm shape.
A global score I was observed in 88 patients and a score II in
61 patients.
2.3. Blood Collection and Laboratory Measurements. CBC
information used in this analysis was from blood sam-
ples drawn from fasting overnight patients via an ante-
cubital vein puncture before AAA resection and commer-
cially available assays were used according to manufacturer’s
instruction. Specimens were collected in peripheral blood
sampling microtainer tube containing K2EDTA and com-
plete blood count was measured with the Coulter LH 750
automatic blood counting system. Red blood cell (RBC)
indices (hemoglobin, Hb; mean corpuscular volume, MCV;
mean corpuscular hemoglobin, MCH; mean corpuscular
hemoglobin concentration, MCHC; and red blood cell dis-
tribution width, RDW), white blood cell (WBC) counts with
differentials (neutrophil; lymphocyte;monocyte, eosinophils,
and basophils) and platelet (PLT) counts data were collected.
NLR was calculated by dividing absolute neutrophil count
by absolute lymphocyte count and PLR as the ratio of
the platelet to lymphocyte. The instruments were calibrated
against appropriate proprietary reference standard material
and verified by using the registered quality controls.
2.4. Statistical Analysis. To analyze the relationships between
calcification and the variables in the dataset, we applied
different test.
First of all, we tested the association between calcification
and the 9 risk factors in the dataset (which are qualitative
variables) using Pearson’s Chi-squared test.
For the 14 quantitative variables related to blood count,
we studied possible relationships with calcification by means
of the nonparametric Wilcoxon signed-rank test since all the
variables (except one) are not normally distributed.Wilcoxon
signed-rank test is a good alternative to 𝑡-test when the
population cannot be assumed to be normally distributed.
Moreover, for the variables related to calcification, we build a
boxplot in order to clearly highlight the differences between
patients with severe calcifications and the others.
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Figure 1: Boxplots for MCV (a) and MCH (b) using grouping variable calcification.
Table 3: Results of the Shapiro-Wilk normality on the variables
related to the blood count.
Shapiro test
Variables p value
WBC 0.0145
RBC 0.0844
Hgb 0.0026
Hct <2.2𝐸 − 16
MCV 4.36𝐸 − 09
MCH 1.56𝐸 − 08
MCHC <2.2𝐸 − 16
RDW 3.90𝐸 − 09
PTL 0.0005
Neutrophils 5.88𝐸 − 15
Lymphocytes 2.75𝐸 − 13
Monocytes 2.56𝐸 − 14
Eosinophils <2.2𝐸 − 16
Basophils 2.96𝐸 − 16
NLR <2.2𝐸 − 16
PLR 2.23𝐸 − 11
MLR <2.2𝐸 − 16
ELR <2.2𝐸 − 16
BLR 2.20𝐸 − 16
These procedures were performed with the statistical
programming language R version 3.2.4.
3. Results
The dataset is composed of 149 observations, 13 females
(8.72%) and 136 males (91.28%). Among them, 88 patients
(59.06%) showed a calcification that covered less than 33%
of aortic circumference while for the remaining 61 the
calcification coveredmore than 33% of aortic circumferences.
Patients differed in age, sex, hypertension, obesity, glucose
tolerance, renal failure, family history of cardiovascular dis-
eases, and chronic obstructive pulmonary disease. As shown
in Table 1, in our data no significant association was found
with the classical risk factors analyzed between patients with
calcification grades I and II.
We then analyzed CBC and, overall, all hematological
indices were within the normal limit according to our
laboratory references. Table 2 reports the descriptive statistics
for the 14 quantitative variables in the dataset related to blood
count.
We note that, for neutrophils, lymphocytes, monocytes,
eosinophils, and basophils, the Interquartile Range (IR,
henceforth) is equal to 0 (there is no variability in the central
interval that contains 50% of the ordered observations).
Table 3 reports the results of Shapiro-Wilk normality test,
pointing out that all the variables (except RBC) are not nor-
mally distributed. These results led us to use nonparametric
Wilcoxon signed-rank test since it does not require particular
assumptions on the distribution of the analyzed variables. In
fact, on this type of data, t-test could lead to biased results.
Wilcoxon 𝑝 values are reported in Table 4.
For completeness, we compute also 𝑡-test for the unique
variable normally distributed RBC which provides similar
results (see Table 5) to the Wilcoxon signed-rank test. We
computed also the following ratios well known in literature:
NLR and PLR. For both we reject the hypothesis of normality
(see Table 3) and we use the Wilcoxon signed-rank test for
understanding potential relationships with wall calcification
(Table 4).
Only MCV and MCH (Table 4) show a significant rela-
tionship with calcification (𝑝 value < 0.05). More precisely,
patients with severe calcification (>33%) have higher median
values for both variables (see also red boxplots in Figures 1(a)
and 1(b)). Since reference values for MCV are different for
men and women, we repeated the Wilcoxon signed-rank test
excluding the 13 females from the analysis. It is interesting to
note that we obtained similar results (see Table 6).
Differently from other studies related to calcification and
other cardiovascular disease, no significant difference was
observed in all the other parameters observed.
4. Discussion
Themain finding in our study is the identification of potential
biomarkers of increased risk of calcification in patients with
AAA.Our results, if confirmed in independent larger studies,
International Journal of Vascular Medicine 5
Table 4: Wilcoxon signed-rank test for variables related to blood count. In bold, p value < 0.05.
Variables Median p value Min–max 95th perc
WBC
Calcification ≤ 33% 7.06 0.8379 3.87–12.52 10.42
Calcification > 33% 6.79 4.20–11.83 10.54
RBC
Calcification ≤ 33% 4.58 0.1488 2.55–6.29 5.30
Calcification > 33% 4.37 2.89–5.40 5.14
Hgb
Calcification ≤ 33% 14.10 0.9047 8.20–17.10 16.03
Calcification > 33% 14.00 9.40–17.30 16.00
Hct
Calcification ≤ 33% 42.45 0.9784 24.30–51.10 47.36
Calcification > 33% 41.80 27.00–401.00 49.30
MCV
Calcification ≤ 33% 93.70 0.0172 65.10–105.20 101.43
Calcification > 33% 95.60 73.20–106.90 101.10
MCH
Calcification ≤ 33% 31.40 0.0168 20.20–35.70 34.13
Calcification > 33% 32.10 23.80–36.80 34.40
MCHC
Calcification ≤ 33% 33.50 0.1402 3.70–35.30 34.40
Calcification > 33% 33.80 32.20–35.50 34.90
RDW
Calcification ≤ 33% 14.20 0.4062 12.20–19.40 17.33
Calcification > 33% 14.10 12.80–19.00 16.90
PTL
Calcification ≤ 33% 189.00 0.6824 11.00–387.00 294.55
Calcification > 33% 188.00 99.00–354.00 265.00
Neutrophils
Calcification ≤ 33% 4.18 0.4997 1.96–9.52 6.36
Calcification > 33% 4.18 2.04–7.78 6.39
Lymphocytes
Calcification ≤ 33% 1.72 0.4597 0.75–3.52 2.75
Calcification > 33% 1.72 0.70–3.16 2.24
Monocytes
Calcification ≤ 33% 0.56 0.6664 0.34–1.12 0.84
Calcification > 33% 0.56 0.34–1.03 0.84
Eosinophils
Calcification ≤ 33% 0.15 0.2171 0.02–22.00 0.39
Calcification > 33% 0.15 0.02–0.64 0.37
Basophils
Calcification ≤ 33% 0.03 0.1931 0.00–0.09 0.06
Calcification > 33% 0.03 0.00–0.06 0.04
NLR
Calcification ≤ 33% 2.43 0.9814 0.80–12.69 4.27
Calcification > 33% 2.43 1.19–11.00 4.25
PLR
Calcification ≤ 33% 107.56 0.7929 4.72–386.67 225.71
Calcification > 33% 109.88 58.23–250.54 205.81
MLR
Calcification ≤ 33% 0.33 0.8441 0.15–1.13 0.52
Calcification > 33% 0.33 0.20–1.29 0.56
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Table 4: Continued.
Variables Median p value Min–max 95th perc
ELR
Calcification ≤ 33% 0.09 0.1405 0.02–14.77 0.23
Calcification > 33% 0.09 0.02–0.36 0.18
BLR
Calcification ≤ 33% 0.02 0.5956 0.00–0.09 0.03
Calcification > 33% 0.02 0.00–0.04 0.03
In bold, 𝑝 values < 0.05.
Table 5: t-test for RBC variable.
Variable Mean p value Min–max 95th perc
RBC
Calcification ≤ 33% 4.45 0.1981 2.55–6.29 5.30
Calcification > 33% 4.32 2.89–5.40 5.14
Table 6: Wilcoxon signed-rank test for MCV and MCH excluding females from the analysis.
Variables Median 𝑝 value Min–max 95th perc
MCV
Calcification ≤ 33% 93.10 0.0060 65.10–105.20 101.50
Calcification > 33% 95.70 73.20–106.90 101.15
In bold, 𝑝 values < 0.05.
may have potential implications for improved prediction,
therapy personalization, and development of novel therapies.
Personalized medicine is the concept promising progress
in modern healthcare, and the biomarkers comprise its
cornerstone [19]. Despite obviously varying rates of calcifi-
cation progression or further clinical destabilization, current
guidelines recommend a universal approach to these “high
risk” patients. Such uniformmanagementmay be responsible
for lack of progress in development of new strategies in
the management of these patients. In our population of 149
patients admitted to the vascular surgery for AAA restriction
we found that well-known risk factors for AAA are not, in
our hands, correlated with different grade of calcification
suggesting that none of the risk factors analyzed can be used
reliably as risk factors for progression of calcification.
As an economic and extensively used basic hematological
test, some parameter of CBC became a target of investigation
after it was found that some of them are associated with mor-
bidity, mortality, and calcification in different cardiovascular
diseases [16, 20, 21].
A large number of studies use t-test to determine if
two sets of data are significantly different from each other,
without checking the normality in the units. For this reason,
we first control the data distribution and we then choose
a tailored approach able to deal with observations non-
normally distributed. Consequently, we are confident that our
results are reliable.
In our analysis we highlight a statistically significant
difference in median values of MCV and MCH (both 𝑝
values are lower than 0.05) in patients with different grade
of calcification of AAA, confirming that these subgroups of
individuals come from different populations.
Reduction in RBC indices, such as MCV and MCH,
accompanies the aging of RBC together with a decrease in
whole cell deformability while rigidity increases this reduc-
tion in deformability which plays a role in the destruction
of the RBC [22–24]. Deformability describes the ability of
RBCs to change shape in response to deforming forces which
not only improves their flow properties but also protects
against cell disruption under bulk flow conditions and in the
circulation when passing through vessels with higher rigidity
caused, for example, by calcification, or with a flow shear
stress caused by the change in the structure of the calcified
AAA [25, 26]. Probably the reason of the higher MCV and
MCH in patient with a higher calcification grade is related to
the fact that older RBCs, with lower MCV and lower MCH,
that have less elasticity died easily following turbulence that
can be present nearby AAA calcification or cannot support
the impact with calcified tissue that has as a consequence a
global MCV and MCH increase.
From our data we found no association of the other
above-mentioned markers with different grade of calcifica-
tion of AAA; this is probably dependent on the fact that
markers described to correlate with calcification of other
districts are not useful for AAA calcification grade, regarding
the heterogeneity between previous studies and our studies
in the studied population and definition of each calcified
group as well as imaging modalities to detect calcification,
and from a methodological point of view statistical analysis
used by most of the other studies was less complex than
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the one we use in our study. Nevertheless, our findings
suggest that none of CBC indices can be used reliably as
a marker of calcification grade of AAA apart from MCV
and MCH that strongly correlate with the different grade of
calcification. This is very important since, beside imaging,
today no accuratemethods exist in order to diagnose calcified
AAAs, and clinical examination is still doubtful and the
management of patients withAAAmight significantly benefit
from the measurement of circulating markers that facilitate
an early diagnosis and that could have a direct correlation
with a possible fast growth of a known lesion with important
limitation such as cost, availability, or waiting time; therefore
the aim of our study is to identify circulating markers that
could substantially help to identify appropriate patients for
different monitoring protocols and intervention. We also
believe that this marker should be available in most of the
laboratories and have a weak economic impact.
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